LDS/Medical Tests/Hydrocodone and Metabolites, Urine

Hydrocodone and Metabolites, Urine

Hydrocodone is a semisynthetic opioid agonist derived from codeine. Hydrocodone is the most commonly prescribed drug in the US and is frequently co-formulated with non-opioid analgesics such as acetaminophen or ibuprofen. Hydrocodone is also co-formulated with drugs such as chlorpheniramine or homatropine in cough syrups. The typical route of administration is oral (tablets, solution, etc). The principle therapeutic metabolite is hydromorphone, which is pharmacologically active and contributes to the analgesic effect of the drug. Because CYP2D6 is a primary metabolic pathway for production of hydomorphone, rapid metabolizers may produce excess hydromorphone while poor metabolizers may not respond well to hydrocodone. In most patients, the metabolites norhydrocodone and hydrocodol (dihydrocodeine stereoisomer) appear at higher concentrations than hydromorphone. Hydrocodone does not form glucuronide conjugates but hydromorphone is eliminated largely as a conjugate. The half-life of immediate release hydrocodone is 3.4-8.8 hours and the half-life of hydromorphone is 3-9 hours.

Approximately 26% of the parent drug (hydrocodone) is excreted into the urine within 72 hours of a dose. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient. 

Common side effects: sedation, nausea, vomiting, dizziness, miosis, constipation, urinary retention, and anxiety. Hydrocodone can also contribute to the following effects: euphoria, mental clouding, amnesia, hostility, irritability, pruritis, and vivid or disturbing dreams. Can be addictive. Overdose effects include respiratory depression and collapse, seizure, coma, and possible death.

Hydrocodone and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result indicates only the presence of Hydrocodone and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Hydromorphone, norhydrocodone, and dihydrocodeine are common metabolites that may be detected after hydrocodone use. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). Immunoassays for opiates are generally sensitive but not specific to hydrocodone. Targeted assays can distinguish between codeine and major metabolites such as norhydrocodone, dihydrocodine, hydromorphone, and the glucuronide conjugates. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection of the metabolite hydromorphone.

Serum (SST). 

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Patients with poor or rapid metabolizer phenotypes for *CYP2D6* may be at risk of therapeutic failure or toxicity with hydrocodone use, respectively. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.